Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3073–3096 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Melanoma
Interventions: Ipilimumab, Placebo, Dacarbazine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 32
States / cities: Anaheim, California • La Verne, California • Los Angeles, California + 28 more

Conditions: Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Venous Leg Ulcers
Interventions: EPA+DHA, placebo; Dietary Supplement · Other
Lead sponsor: Ohio State University; Other
Eligibility: 55 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer
Interventions: Exercise; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Durate, California • San Carlos, California • Basking Ridge, New Jersey + 6 more

Conditions: Rosacea
Interventions: Azelaic acid; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 41
States / cities: Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more

Conditions: Breast Cancer
Interventions: PBI Radiotherapy 6 Gy, PBI Radiotherapy 8 Gy; Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions: IDE034; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 22
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 17 more

Conditions: Atopic Dermatitis
Interventions: Oregano extract cream, Hydrocortisone; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Pressure Ulcer
Interventions: dHACM; Procedure
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Breast Cancer
Interventions: protein analysis, protein expression analysis, proteomic profiling, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, liquid chromatography, mass spectrometry, fine-needle aspiration, needle biopsy, radiomammography; Genetic · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer, Metastatic Breast Cancer (MBC)
Interventions: Romosozumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions: Apligraf, Standard dressing regimen; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Stanford, California • Miami, Florida • New York, New York + 2 more

Conditions: Vasculitis
Interventions: Placebo, Belimumab 10 mg/kg, Azathioprine; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more

Conditions: Pemphigus
Interventions: Sirolimus (formerly known as Rapamycin); Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Irvine, California

Conditions: Metastatic Melanoma
Interventions: High Dose Interleukin-2, Ipilimumab; Drug
Lead sponsor: Clinigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more

Conditions: Breast Cancer
Interventions: Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion, 3D conformal radiation therapy; Drug · Radiation
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more

Conditions: Melanoma
Interventions: Nivolumab, Hydroxychloroquine, Ipilimumab; Drug
Lead sponsor: Ravi Amaravadi, MD; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1989 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Melanoma
Interventions: Nivolumab +/- ipilimumab, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Up to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Dedicated breast computed tomography imaging; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alopecia Areata
Interventions: Farudodstat, Placebo; Drug
Lead sponsor: ASLAN Pharmaceuticals; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Birmingham, Alabama • Fountain Valley, California • Santa Ana, California + 16 more

Conditions: Melanoma
Interventions: EGIR Tape; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

Researching the Effect of Exercise on Cancer

Azelaic Acid on Demodex Counts in Rosacea

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

A Single Center, Prospective, Case Series of the Treatment of Pressure Ulcers and Decubitus Ulcers.

Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease

A Study of Romosozumab in People With Breast Cancer and Osteoporosis

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Belimumab in Remission of VASculitis

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Chemotherapy Monitoring With Breast Computed Tomography (CT)

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells